A Phase 2a Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MEDI0382 in Overweight/Obese Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 04 Feb 2019
At a glance
- Drugs MEDI 0382 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors MedImmune
- 25 Jan 2019 Planned End Date changed from 7 Jun 2019 to 10 Jun 2019.
- 25 Jan 2019 Planned primary completion date changed from 7 Jun 2019 to 10 Jun 2019.
- 25 Jan 2019 Status changed from not yet recruiting to recruiting.